In it to bring hope to people with cancer.
Roger joined Seagen as Chief Medical Officer in 2018, bringing extensive experience in cancer drug development. He was appointed President, Research and Development in 2022. His deep oncology background and proven leadership has helped Seagen evolve into a global, multi-product oncology company.
Previously, Roger was Therapeutic Area Head for Late-Stage Oncology at Merck & Co., Inc., where he was responsible for registration efforts for Keytruda® (pembrolizumab) across multiple tumor types. Earlier in his career, Roger was the Vice President of Oncology Clinical Research at Gilead Sciences and the Global Development Lead for Xgeva® (denosumab) at Amgen, where he held multiple roles in oncology and hematology.
Roger holds an M.D. from the University of Witwatersrand in Johannesburg, South Africa. He serves as a member of the board of directors for INOVIO Pharmaceuticals, Inc. and Kronos Bio, Inc.